CY1112540T1 - Αμορφη μορφη της (11βητα,16αλφα)-9-φθορο-11-υδροξυ-16,17-[(μεθυλοαιθυλιδενο)δι(οξυ)]-21-[(4-[(νιτροοξυ)μεθυλο]βενζοϋλ]οξυ]-πρεγνα-1,4-διεν-3,20-διονης - Google Patents
Αμορφη μορφη της (11βητα,16αλφα)-9-φθορο-11-υδροξυ-16,17-[(μεθυλοαιθυλιδενο)δι(οξυ)]-21-[(4-[(νιτροοξυ)μεθυλο]βενζοϋλ]οξυ]-πρεγνα-1,4-διεν-3,20-διονηςInfo
- Publication number
- CY1112540T1 CY1112540T1 CY20111100675T CY111100675T CY1112540T1 CY 1112540 T1 CY1112540 T1 CY 1112540T1 CY 20111100675 T CY20111100675 T CY 20111100675T CY 111100675 T CY111100675 T CY 111100675T CY 1112540 T1 CY1112540 T1 CY 1112540T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nitrooxy
- amorphous form
- dionis
- methylthioethylene
- 16alpha
- Prior art date
Links
- -1 4 - [(Nitrooxy) Methyl] -phenyl Chemical group 0.000 title 1
- AMBKPYJJYUKNFI-UHFFFAOYSA-N methylsulfanylethene Chemical group CSC=C AMBKPYJJYUKNFI-UHFFFAOYSA-N 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 125000001893 nitrooxy group Chemical class [O-][N+](=O)O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
Η εφεύρεση αφορά στο τεχνικό πεδίο των αντιφλεγμονωδών ενώσεων, συγκεκριμένα εκείνων στεροειδούς φύσης, ειδικότερα σε μια νέα άμορφη μορφή ενός νιτροοξυ παραγώγου ενός κορτικοστεροειδούς, στα φαρμακευτικά σκευάσματα αυτού και στη χρήση του στην θεραπεία ή την πρόληψη ασθενειών ή συμπτωμάτων του δέρματος ή των βλεννογόνων μεμβρανών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200702796A ES2324007A1 (es) | 2007-10-25 | 2007-10-25 | Una forma amorfa de un compuesto antiinflamatorio. |
EP08841744A EP2205620B1 (en) | 2007-10-25 | 2008-10-23 | Amorphous form of (11beta,16alpha)-9-fluoro-11-hydroxy-16,17-[(1-methylethyliden)bis(oxy)]-21-[[4- [(nitrooxy)methyl]benzoyl]oxy]-pregna-1,4-dien-3,20-dione |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112540T1 true CY1112540T1 (el) | 2015-12-09 |
Family
ID=40377713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100675T CY1112540T1 (el) | 2007-10-25 | 2011-07-12 | Αμορφη μορφη της (11βητα,16αλφα)-9-φθορο-11-υδροξυ-16,17-[(μεθυλοαιθυλιδενο)δι(οξυ)]-21-[(4-[(νιτροοξυ)μεθυλο]βενζοϋλ]οξυ]-πρεγνα-1,4-διεν-3,20-διονης |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100261691A1 (el) |
EP (1) | EP2205620B1 (el) |
JP (1) | JP2011500762A (el) |
KR (1) | KR20100091159A (el) |
CN (1) | CN101861327B (el) |
AT (1) | ATE505477T1 (el) |
AU (1) | AU2008316471A1 (el) |
BR (1) | BRPI0818822A2 (el) |
CA (1) | CA2703441A1 (el) |
CY (1) | CY1112540T1 (el) |
DE (1) | DE602008006244D1 (el) |
DK (1) | DK2205620T3 (el) |
ES (2) | ES2324007A1 (el) |
MX (1) | MX2010004423A (el) |
PL (1) | PL2205620T3 (el) |
PT (1) | PT2205620E (el) |
RU (1) | RU2010120844A (el) |
SI (1) | SI2205620T1 (el) |
WO (1) | WO2009053439A2 (el) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2318427T3 (da) * | 2008-07-31 | 2014-01-20 | Nicox Sa | Glucocorticoider bundet til nitratestere via en aromatisk linker i position 21 og deres anvendelse i oftalmologi |
ES2359708B1 (es) * | 2009-11-16 | 2012-03-30 | Ferrer Internacional S.A. | Procedimiento de preparación de la (11beta,16alfa)-9-fluoro-11-hidroxi-16,17-[1-metil-etilidenebis(oxi)]-21-[1-oxo-[4-(nitrooximetil)benzoxi]]preña-1,4-dien-3,20-diona. |
RU2629601C1 (ru) * | 2016-11-03 | 2017-08-30 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Казанская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ лечения больных красным плоским лишаем |
RU2709534C1 (ru) * | 2018-07-12 | 2019-12-18 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) | Способ лечения хронических дерматозов |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1312115B1 (it) * | 1999-06-24 | 2002-04-04 | Nicox Sa | Composti amorfi e relative composizioni farmaceutiche |
US8313504B2 (en) * | 2000-09-18 | 2012-11-20 | Cordis Corporation | Foam matrix embolization device |
ITMI20020148A1 (it) * | 2002-01-29 | 2003-07-29 | Nicox Sa | Nuovi corticosteroidi |
EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
US20060045850A1 (en) * | 2004-08-30 | 2006-03-02 | Qpharma, Llc | Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids |
AU2006286838C1 (en) * | 2005-09-02 | 2013-05-02 | Ferrer Internacional S.A. | Nitrooxy derivatives of glucocorticoids |
-
2007
- 2007-10-25 ES ES200702796A patent/ES2324007A1/es not_active Withdrawn
-
2008
- 2008-10-23 ES ES08841744T patent/ES2364953T3/es active Active
- 2008-10-23 DK DK08841744.9T patent/DK2205620T3/da active
- 2008-10-23 RU RU2010120844/04A patent/RU2010120844A/ru not_active Application Discontinuation
- 2008-10-23 WO PCT/EP2008/064387 patent/WO2009053439A2/en active Application Filing
- 2008-10-23 AU AU2008316471A patent/AU2008316471A1/en not_active Abandoned
- 2008-10-23 EP EP08841744A patent/EP2205620B1/en not_active Not-in-force
- 2008-10-23 JP JP2010530461A patent/JP2011500762A/ja active Pending
- 2008-10-23 CN CN2008801131050A patent/CN101861327B/zh not_active Expired - Fee Related
- 2008-10-23 CA CA2703441A patent/CA2703441A1/en not_active Abandoned
- 2008-10-23 US US12/739,131 patent/US20100261691A1/en not_active Abandoned
- 2008-10-23 MX MX2010004423A patent/MX2010004423A/es active IP Right Grant
- 2008-10-23 PL PL08841744T patent/PL2205620T3/pl unknown
- 2008-10-23 DE DE602008006244T patent/DE602008006244D1/de active Active
- 2008-10-23 SI SI200830287T patent/SI2205620T1/sl unknown
- 2008-10-23 AT AT08841744T patent/ATE505477T1/de active
- 2008-10-23 BR BRPI0818822 patent/BRPI0818822A2/pt not_active IP Right Cessation
- 2008-10-23 PT PT08841744T patent/PT2205620E/pt unknown
- 2008-10-23 KR KR1020107008681A patent/KR20100091159A/ko not_active Application Discontinuation
-
2011
- 2011-07-12 CY CY20111100675T patent/CY1112540T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI2205620T1 (sl) | 2011-08-31 |
WO2009053439A3 (en) | 2009-07-16 |
BRPI0818822A2 (pt) | 2015-04-22 |
WO2009053439A2 (en) | 2009-04-30 |
CN101861327A (zh) | 2010-10-13 |
KR20100091159A (ko) | 2010-08-18 |
MX2010004423A (es) | 2010-09-10 |
AU2008316471A1 (en) | 2009-04-30 |
JP2011500762A (ja) | 2011-01-06 |
ES2364953T3 (es) | 2011-09-19 |
EP2205620A2 (en) | 2010-07-14 |
PL2205620T3 (pl) | 2011-10-31 |
ES2324007A1 (es) | 2009-07-28 |
EP2205620B1 (en) | 2011-04-13 |
PT2205620E (pt) | 2011-07-12 |
CA2703441A1 (en) | 2009-04-30 |
US20100261691A1 (en) | 2010-10-14 |
RU2010120844A (ru) | 2011-11-27 |
DE602008006244D1 (de) | 2011-05-26 |
CN101861327B (zh) | 2012-10-31 |
DK2205620T3 (da) | 2011-07-25 |
ATE505477T1 (de) | 2011-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29779A1 (es) | Nitrooxi derivados de esteroides | |
CY1123549T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
CY1118672T1 (el) | Συνθεσεις ταπενταδολης | |
CO6351743A2 (es) | Inhibidores ciclicos de 11beta-hidroxiesteroide deshidrogenasa 1 | |
GT200500360A (es) | Compuestos organicos | |
CY1118236T1 (el) | Μεθοδος για αντισυλληψη κατ' απαιτηση | |
CY1123485T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια νοσων | |
CY1115477T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
BR112013019256A2 (pt) | inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune | |
BR112013002601A2 (pt) | corticosteróides para o tratamento de dor em articulação | |
CY1111454T1 (el) | Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων | |
CY1112540T1 (el) | Αμορφη μορφη της (11βητα,16αλφα)-9-φθορο-11-υδροξυ-16,17-[(μεθυλοαιθυλιδενο)δι(οξυ)]-21-[(4-[(νιτροοξυ)μεθυλο]βενζοϋλ]οξυ]-πρεγνα-1,4-διεν-3,20-διονης | |
CY1111541T1 (el) | Αγωνιστες β-2 αδρενοϋποδοχεα για την αγωγη παθησεων συνδετικου ιστου του δερματος | |
BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
BR112014018953A8 (pt) | Derivados de lupano triterpenoide e uso farmacêutico dos mesmos | |
CY1118081T1 (el) | Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες | |
WO2008012338A3 (en) | Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions | |
CL2011003144A1 (es) | Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05). | |
BRPI0607795A2 (pt) | compostos antiinflamatórios | |
CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
CY1115384T1 (el) | Αντι-φλεγμονωδης συνθεση | |
WO2007136910A3 (en) | Eimmunotherapy for immune suppressed patients | |
BR112012029697A2 (pt) | polissacarídeo da semente de tamarindo para uso no tratamento de doenças inflamatórias | |
SE0400346D0 (sv) | Steroids for cancer treatment | |
NO20075758L (no) | Polymorfer av 3-0-(3',3'-dimetylsuccinyl) betulin syre di-N-metyl-D-glukamin |